Advanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
|
|
- Marilynn Marshall
- 5 years ago
- Views:
Transcription
1 Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
2 Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of December The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Creative Educational Concepts or the supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
3 Usage Rights This slide deck is provided for educational purposes and slides may be used for personal, noncommercial presentations only as long as content and references remain the same. No part of this slide deck may be published or distributed in print or electronic format without prior written permission from Creative Educational Concepts.
4 Accreditation Physicians: 1.0 AMA PRA Category 1 Credit(s) Pharmacists: 1.0 ACPE contact hour (.10 CEUs) Nurses: 1.0 contact hour Faculty Information: You can find your faculty member s full bio and disclosure in your handout or online at Special Thanks! Supported through an independent educational grant from Astellas and Sanofi, a Genzyme Company. Presented by Creative Educational Concepts, Inc. (CEC)
5 Learning Objectives 1) Review the spectrum of advanced prostate cancer, including castration-resistant prostate cancer (CRPC), the currently available treatment options, unmet clinical needs, and treatment disparities among specific patient populations. 2) Appraise the safety and efficacy of current treatment options for advanced prostate cancer, including CRPC, and rational sequencing strategies for these treatment options across the spectrum of disease. 3) Design individualized treatment plans for advanced prostate cancer as part of an interprofessional healthcare team with a focus on shared decision making. 4) Evaluate the safety and efficacy of emerging treatment options for recurrent advanced prostate cancer, including novel androgen receptor axis-targeting agents.
6 Prostate Cancer Disease States mcspc Localized Disease mcrpc L1 mcrpc L2 mcrpc L2+ Biochemical Recurrence nmcrpc mcspc=metastatic castration-sensitive prostate cancer; nmcrpc=nonmetastatic castration-resistant prostate cancer; mcrpc=metastatic castration-resistant prostate cancer; L=line of treatment.
7 Prostate Cancer Disease States mcspc Localized Disease mcrpc L1 mcrpc L2 mcrpc L2+ Biochemical Recurrence nmcrpc mcspc=metastatic castration-sensitive prostate cancer; nmcrpc=nonmetastatic castration-resistant prostate cancer; mcrpc=metastatic castration-resistant prostate cancer; L=line of treatment.
8 Incidence of mpca relative to 2004 Metastatic Prostate Cancer Incidence in US: Age, years < Year of Diagnosis Weiner AB, et al. Prostate Cancer Prostatic Dis
9 DRUG USAGE Metastatic Prostate Cancer Treatment Patterns: Retrospective Analysis of Real-World Data 1 100% 90% 80% 70% 60% 50% 40% 30% 20% Sipuleucel-T Cabazitaxel Enzalutamide Abiraterone acetate Estramustine Mitoxantrone 10% 0% AGE GROUP (years) > > > > Docetaxel The M1 populations reported in clinical trials do not represent real-life patients with M1 disease 2 The treatment guidelines are commonly not followed in everyday practice 1 Flaig TW, et al. Cancer Med. 2016; 2 Flaig TW, et al. Clin Genitourin Cancer
10 mcrpc Therapies With Survival Benefit Agent Year Approved Indication PFS Benefit OS Benefit Docetaxel mcrpc? Yes Sipuleucel-T Asymptomatic or minimally symptomatic mcrpc No Yes Cabazitaxel Post-docetaxel mcrpc Yes Yes Abiraterone 4, and 2012 mcrpc Yes Yes Enzalutamide and 2014 mcrpc Yes Yes Radium Symptomatic bone predominant mcrpc SSRE Yes 1 Tannock IF, et al. N Engl J Med. 2004; 2 Kantoff PW, et al. N Engl J Med. 2010; 3 de Bono JS, et al. Lancet. 2010; 4 de Bono J, et al. N Engl J Med. 2011; 5 Ryan CJ, et al. N Engl J Med. 2013; 6 Scher HI, et al. N Engl J Med. 2012; 7 Parker C, et al. N Engl J Med
11 mcrpc Non-Chemotherapy Treatment Options
12 Abiraterone Before Chemotherapy COU-AA-302 Phase 3 Trial: PFS Progression-free Survival (%) Radiographic Progression-free Survival (PFS) Hazard ratio, 0.53 (95% CI, ) P<0.001 Abiraterone-prednisone, 16.5 mo Prednisone alone, 8.3 mo No. of Events Abiraterone-prednisone:271 Prednisone alone: Number at risk Abiraterone prednisone Prednisone alone Time (months) Ryan CJ, et al. N Engl J Med. 2013; Ryan CJ, et al. Lancet Oncol
13 Abiraterone Before Chemotherapy COU-AA-302 Phase 3 Trial: OS Overall Survival (%) Median Overall Survival (OS) Abiraterone acetate plus prednisone 34.7 months (95% CI ) Placebo plus prednisone 30.3 months (95% CI ) HR 0.81 (95% CI ) P= Number at risk Abiraterone acetate plus prednisone Placebo plus prednisone Time (months) Ryan CJ, et al. N Engl J Med. 2013; Ryan CJ, et al. Lancet Oncol
14 Enzalutamide Before Chemotherapy PREVAIL Phase 3 Trial: PFS rpfs (%) Enzalutamide Placebo Median rpfs (95% CI), mo 20 ( ) 5.4 ( ) HR (95% CI); P value 0.32 ( ); P< Patients at risk Enzalutamide Placebo Enzalutamide Placebo mo Beer TM, et al. N Engl J Med. 2014; Beer TM, et al. Eur Urol
15 Enzalutamide Before Chemotherapy PREVAIL Phase 3 Trial: OS OS (%) Patients at risk Enzalutamide Placebo Enzalutamide Placebo Enzalutamide Placebo Median OS (95% CI), mo 35.3 (32.2-NYR) 31.3 ( ) HR (95% CI); P value mo ( ); P= Beer TM, et al. N Engl J Med. 2014; Beer TM, et al. Eur Urol
16 Maximum PSA Change on Enzalutamide Enzalutamide PSA Decline by Prior Therapy Abiraterone + Docetaxel-Naïve N=36 Prior Therapy Maximum PSA Decrease on Enzalutamide 0-30% 30-50% 50-90% % Abiraterone + docetaxel-naïve, N=36 27 (75) 24 (67) 21 (58) 8 (22) Prior abiraterone, N=79 47 (59) 22 (28) 14 (18) 2 (3) Prior docetaxel, N=30 16 (53) 13 (43) 9 (30) 4 (13) Prior abiraterone + docetaxel, N= (46) 40 (24) 28 (17) 4 (2) Cheng HH, et al. Prostate Cancer Prostatic Dis
17 Improving Hormonal Therapy Strategies More complete suppression of androgen production Abiraterone More complete blockade of androgen receptor signaling Enzalutamide Apalutamide (ARN-509) Darolutamide (ODM-201) Merseburger AS, et al. Onco Targets Ther. 2016; Francini E, Taplin ME. Cancer
18 Immunotherapy for mcrpc Sipuleucel-T Autologous APCs Cultured With Antigen Fusion Protein Mulders PF, et al. Cancer Immunol Immunother
19 Sipuleucel-T IMPACT Phase 3 Trial: OS FDA approved based on HR of 0.78 Survival curves separated after 6 months Treatment is carried out in 5 weeks Few side effects Placebo Sip-T HR; P N Median OS, mo ;.03 Kantoff PW, et al. N Engl J Med
20 Sipuleucel-T OS by Baseline PSA Survival Benefit May be Better in Patients with Lower Baseline PSA Baseline PSA 22.1 (N=128) > (N=128) > (N=128) >134.1 (N=128) Median OS Sipuleucel-T, mo Median OS Control, mo Difference HR Schellhammer PF, et al. Urology
21 Targeting Bone Metastases Radium-223 a-particles induce dsdna breaks in adjacent tumor cells Short penetration of a emitters (2-10 cell diameters)=highly localized tumor cell killing and minimal damage to surrounding normal tissue Shore ND. Urology
22 Radium-223 ALSYMPCA Phase 3 Trial Symptomatic CRPC 2 bone metastases No known visceral metastases or >3- cm nodes Post-docetaxel or unfit for docetaxel or refusing docetaxel N=921 2:1 ARM A Radium-223 (50 kbq/kg) + Best standard of care 6 injections at 4-week intervals ARM B Placebo + Best standard of care Stratifications: Total ALP: <220 U/L vs 220 U/L; Bisphosphonates: Yes vs No; Prior docetaxel: Yes vs No. Parker C, et al. N Engl J Med
23 Radium-223 ALSYMPCA Phase 3 Trial: OS Parker C, et al. N Engl J Med Placebo Radium-223 HR; P N Median OS, mo ; <.001
24 mcrpc Chemotherapy Treatment Options
25 Docetaxel TAX 327 Phase 3 Trial: OS Median OS: 18.9 vs 16.5 mo HR=0.76 (CI: ) P=.009 Outcome, % DOC Q3W (N=296) DOC Q1W (N=297) M Pain response 35 (P=.01) 31 (P=.07) 22 PSA response 45 (P=.005) 45 (P<.001) 32% QoL response (FACT-P) 22 (P=.009) 23 (P=.005) 13 Objective response Tannock IF, et al. N Engl J Med
26 Cabazitaxel TROPIC Phase 3 Trial: PFS and OS Patients with Progressive Disease During or After Docetaxel Treatment PFS OS Mitoxantrone Cabazitaxel Mitoxantrone Prednisone Cabazitaxel Prednisone N MR; P Median OS, mo ; <.0001 Median PFS, mo ; <.0001 de Bono JS, et al. Lancet
27 Cabazitaxel vs Docetaxel FIRSTANA Phase 3 Trial Chemotherapy -Naïve mcrpc N=1168 ARM A Cabazitaxel 25 mg/m 2 Prednisone ARM B Cabazitaxel 20 mg/m 2 Prednisone ARM C Docetaxel Prednisone Until progression or unacceptable toxicity Primary Endpoint: OS C20 and C25 did not demonstrate superiority for OS Among secondary endpoints, only tumor responses were significantly superior for C25 AEs were less frequent in C20 for most categories Sartor AO, et al. ASCO
28 Docetaxel Post-Abiraterone N PSA decline >50%, % PR, % Median Time to PSA Progression, mo Median OS, mo Chemo Cycles Mezynski (All Patients) (2-12) Mezynski (ABI Refractory ) (2-10) Aggarwal (All Patients) Azad (ABI Responders) NR (113) Azad (ABI Non-Responders) NR (1-10) Mezynski J, et al. Ann Oncol. 2012; Aggarwal RR, et al. Clin Genitourin Cancer. 2014; Aggarwal RR, et al. J Clin Oncol. 2012; Azad A, et al. J Clin Oncol
29 Chemotherapy in mcrpc Summary Docetaxel remains the standard first-line chemotherapy Docetaxel is active in patients previously treated with abiraterone and enzalutamide Cabazitaxel is the standard second-line chemotherapy Cabazitaxel yields similar OS when compared to docetaxel as first line chemotherapy Cabazitaxel 20 mg/m 2 dosing yields equivalent survival to the higher dose with less toxicity
30 mcspc ADT + Chemotherapy
31 ADT + Docetaxel CHAARTED Phase 3 Trial N=790; median age of 63 years Stratification: Extent of Mets: high vs low Age: 70 vs <70 years ECOG PS: 0-1 vs 2 CAB >30 days: yes vs no SRE prevention: yes vs no Prior adjuvant ADT: 12 vs >12 months ARM A: ADT + docetaxel 75 mg/m 2 every 21 days for a maximum of 6 cycles Evaluate Q3W while on docetaxel and at week 24, then every 12 weeks Follow for TTP and OS ARM B: ADT-only Evaluate every 12 weeks Chemotherapy at investigators discretion at progression Primary endpoint: OS ADT allowed up to 120 days prior to randomization Intermittent ADT dosing was not allowed Standard dexamethasone premedication, but no daily prednisone Sweeney CJ, et al. N Engl J Med
32 CHAARTED Phase 3 Trial Primary Endpoint: OS Sweeney CJ, et al. N Engl J Med
33 CHAARTED Phase 3 Trial OS by Disease Volume For high-volume metastatic disease, there is a 17-month improvement in median OS from 32.2 months to 49.2 months Sweeney CJ, et al. N Engl J Med
34 CHAARTED Phase 3 Trial Subgroup Analysis: HR for Death Subgroup No. of Patients Hazard Ratio (95% CI) All patients Age 790 <70 yr 612 >70 yr 178 ECOG performance-status score 0 1 or 2 Race White Other or unknown Volume of metastases Low High Type of metastases Visceral metastases with or without bone metastases High-volume disease with bone metastases alone Gleason score <8 >8 Sweeney CJ, et al. N Engl J Med ( ) 0.68 ( ) 0.43 ( ) 0.71 ( ) 0.42 ( ) 0.62 ( ) 0.32 ( ) 0.60 ( ) 0.60 ( ) 0.52 ( ) 0.64 ( ) ( ) ( ) ADT plus Docetaxel Better ADT Alone Better
35 SOC ± Docetaxel ± Zoledronic Acid STAMPEDE Phase 3 Trial N=2,962 M+ (n=1,817; 61%) N+/X M0 (n=448; 15%) N0M0 (n=697; 24%) Median age of 65 years 2:1:1:1 SOC-only SOC + ZA SOC + Doc Primary endpoint: OS ZA: 4 mg for six Q3W cycles, then Q4W until two years Doc: 75 mg/m 2 for six Q3W cycles with prednisolone 10 mg daily Randomly assigned between Oct 5, 2005 and March 31, 2013 James ND, et al. Lancet SOC + ZA + Doc
36 STAMPEDE Phase 3 Trial FFS and OS Median OS: 71 months for SOC-only or SOC + ZA 81 months for SOC + Doc 76 months for SOC + ZA + Doc James ND, et al. Lancet
37 STAMPEDE Phase 3 Trial Treatment Effect by Metastatic Status: OS SOC vs SOC + ZA Metastasis status M0 M1 Overall SOC-only SOC + ZA Hazard ratio HR (95% CI) 65/ /724 31/ / ( ) 0.93 ( ) 0.94 ( ) Favors SOC + ZA Favors SOC SOC vs SOC + Doc Metastasis status M0 M1 Overall 65/ /724 31/ / ( ) 0.76 ( ) 0.78 ( ) Favors SOC + Doc Favors SOC SOC vs SOC + ZA + Doc Metastasis status M0 65/460 M1 350/724 Overall 29/ / Favors SOC + ZA + Doc Favors SOC 0.98 ( ) 0.79 ( ) 0.82 ( ) James ND, et al. Lancet
38 mcspc Management Summary Data from two large prospective trials demonstrate clear evidence of the survival benefit of ADT + docetaxel, which should now be considered the standard of care. Select patients should be managed with ADT alone, based on their comorbidities and performance status. Sweeney CJ, et al. N Engl J Med. 2015; James ND, et al. Lancet
39 Advanced Prostate Cancer Treatment Options and Sequencing
40 mcspc Therapy ADT ADT + docetaxel Strongly consider in the setting of high-volume disease Clinical trial Valenca LB, et al. Cancer Treat Rev
41 mcrpc 1 st -Line Therapy Sipuleucel-T In the setting of minimally symptomatic, low disease burden Enzalutamide or abiraterone Docetaxel In the setting of symptomatic or visceral metastasis Radium-223 In the setting of extensive, symptomatic bone disease, or if unfit for docetaxel Clinical trial Valenca LB, et al. Cancer Treat Rev
42 mcrpc 2 nd -Line Therapy: Post-Docetaxel Enzalutamide or abiraterone Cabazitaxel Radium-223 In the setting of extensive, symptomatic bone disease Sipuleucel-T In the setting of slowly progressive disease Clinical trial Valenca LB, et al. Cancer Treat Rev
43 mcrpc 2 nd -Line Therapy: Post-AR-Targeted Agents Docetaxel Enzalutamide or abiraterone Radium-223 In the setting of extensive, symptomatic bone disease Sipuleucel-T In the setting of minimally symptomatic, low disease burden Clinical trial Valenca LB, et al. Cancer Treat Rev
44 mcrpc 3 rd - and 4 th -Line Therapy Chemotherapy Enzalutamide or abiraterone Radium-223 Clinical trial Valenca LB, et al. Cancer Treat Rev
45 mcrpc Treatment Selection By Clinical Features Clinical Feature Bone predominance Visceral metastases Sipuleucel-T Enzalutamide Abiraterone Docetaxel Cabazitaxel Radium- 223 = = = = = = = = Galloping disease = = = Low performance status = Pain = = = = = There are many other clinical features of tumor and patients that influence therapy decisions Courtesy of Tomasz M. Beer, MD. More likely to prescribe Less likely to prescribe = No effect on prescribing Contraindicated
46 mcrpc Treatment Selection By Prior Therapy and Tumor Histology Clinical Feature Prior enzalutamide or abiraterone Prior docetaxel Small cell histology Anaplastic histology Sipuleucel-T Enzalutamide Abiraterone Docetaxel Cabazitaxel Radium- 223 = = = = = * =*** =*** ** = *Cisplatin-containing chemotherapy is indicated; **docetaxel with cisplatin considered; ***AR expression may influence decision More likely to prescribe Less likely to prescribe Courtesy of Tomasz M. Beer, MD. = No effect on prescribing Contraindicated
47 Sequencing Therapy Abiraterone and Enzalutamide Prior Docetaxel N Abiraterone after enzalutamide PSA Decline 30%, % PSA Decline 50%, % Median TTP, mo Median PFS, mo Noonan Y NR 3.5 Loriot Y NR 2.7 Enzalutamide after abiraterone Schrader Y * - Bianchini Y Badrising Y Cheng Y Azad Y Cheng N Azad N *Responders PSA=prostate specific antigen; TTP=time to progression; PFS=progression-free survival; mo=months. Noonan KL, et al. Ann Oncol. 2013; Loriot Y, et al. Ann Oncol. 2013; Schrader AJ, et al. Eur Urol. 2014; Bianchini D, et al. Eur J Cancer. 2014; Badrising S, et al. Cancer. 2014; Cheng HH, et al. J Clin Oncol. 2014; Azad AA, et al. Eur Urol
48 Sequencing Therapy (cont.) Abiraterone and Enzalutamide Enza then Abi Abi then Enza Log Rank Test, P=.081 Miyake H, et al. Clin Genitourin Cancer. 2016; Maughan BL, et al. Prostate
49 Sequencing Therapy Docetaxel After Abiraterone N PSA decline >50%, % PR, % Median Time to PSA Progression, mo Median OS, mo Chemo Cycles Mezynski (All Patients) (2-12) Mezynski (ABI Refractory ) (2-10) Aggarwal (All Patients) Azad (ABI Responders) NR (113) Azad (ABI Non-Responders) NR (1-10) Mezynski J, et al. Ann Oncol. 2012; Aggarwal RR, et al. Clin Genitourin Cancer. 2014; Aggarwal RR, et al. J Clin Oncol. 2012; Azad AA, et al. J Clin Oncol
50 Sequencing Therapy Cabazitaxel After Abiraterone/Enzalutamide N Prior Docetaxel Prior AA or ENZA PSA Decline 50%, % ORR, % Median PFS, mo Median OS, mo Pezaro 37 Y Y Sella 24 Y Y Saad 26 Y Y AA=abiraterone; ENZA=enzalutamide; PSA=prostrate serum antigen; ORR=objective response rate; PFS=progression-free survival; OS=overall survival. Pezaro CJ, et al. Eur Urol. 2014; Sella A, et al. Clin Genitourin Cancer. 2014; Saad F, et al. J Clin Oncol
51 Predictive Biomarkers Are Needed!
52 Advanced Prostate Cancer Integrative Clinical Genomics Robinson D, et al. Cell
53 Somatic and Germline Aberrations Integrative mcrpc Landscape Analysis Robinson D, et al. Cell
54 Emerging Biomarkers Clinical Utility None in routine clinical use yet Allocation to investigational trials DDR deficiency Double stranded break repair defects BRCA1, BRCA2, ATM, others DNA mismatch repair deficiency microsatellite instability, hypermutated phenotype, MLH, MSH, and others PI3K pathway Raf kinases AR defects Amplification Resistance mutations Splice variants AR-V7
55 Enzalutamide-Resistant mcrpc Evidence of Anti-PD-1 Activity Patients with evidence of progression on enzalutamide were treated with pembrolizumab 200 mg IV every 3 weeks for 4 doses Pembrolizumab was added to standard dose enzalutamide 5 of 27 (19%) patients had a confirmed PSA response 3 of 5 had measurable disease with at least a PR by radiographic assessment 4 of 19 (21%) patients had stable disease > 6 months (range weeks) None of the 5 responders have relapsed Median PFS was 34 weeks There have been seven Grade 3 or higher iraes Graff JN, et al. Oncotarget. 2016; Graff JN, et al. ESMO 2016.
56 Responder 1 Responder 1 Baseline Week 24 Baseline Week 24 Responder 3 Responder 3 Baseline Week 24 Baseline Week 24 Responder 5 Responder 5 Baseline Week 12 Baseline Week 12
57 Proportion of Patients Olaparib in DDR-Deficient CRPC TOPARP-A Phase 2 Trial: rpfs Radiologic Progression-free Survival 1.00 P<.001 by log-rank test 0.75 Biomarker-positive, median: 9.8 mo Biomarker-negative, median: 2.7 mo Months since Trial Entry Mateo J, et al. N Engl J Med
58 Proportion of Patients Olaparib in DDR-Deficient CRPC TOPARP-A Phase 2 Trial: OS Overall Survival 1.00 P=.05 by log-rank test 0.75 Biomarker-positive, median: 13.8 mo Biomarker-negative, median: 7.5 mo Months since Trial Entry Mateo J, et al. N Engl J Med
59 Androgen Receptor Splice Variants The Androgen Receptor and its Ligand-Independent Variants Nakazawa M, et al. Horm Cancer
60 AR-V7-expressing CRPC Response to Treatment Study Antonarakis, et al. Steinestel, et al. Therapeutic Prevalence of AR- V7 (%) PSA response in AR-V7 + vs AR-V7 Patients (%) Abiraterone 19% 0% vs 68% (P<.01) Enzalutamide 39% 0% vs 53% (P<.01) Abiraterone or enzalutamide 64% 7% vs 63% (P=.01) Todenhofer, et al. Abiraterone 11% 0% vs 42% (P=.01) Antonarakis, et al. Docetaxel or cabazitaxel 46% 41% vs 65% (P=.19) Onstenck, et al. Cabazitaxel 55% 8% vs 22% (P=.07) Bryce AH, Antonarakis ES. Int J Urol
61 AR-V7 Summary AR-V7 warrants further evaluation as a potential predictive biomarker May be associated with primary and acquired resistance Potential to select patients who may not benefit from AR-targeted therapy May help guide future sequencing of agents Could fuel development of N-terminal domain inhibitors A prospective, randomized control trial is necessary to validate AR-V7 as a predictive biomarker AR-V7 predictive potential prior to docetaxel should be explored
62 Personalizing Therapy Today Examples Clinical features of disease presentation Sites of disease (bone predominant vs visceral) Pace of disease Presence or absence of significant symptoms Patient health status Performance status Co-morbidities relevant to tolerability of treatment Therapy history Prior enzalutamide or abiraterone Prior chemotherapy Tumor histology Small cell carcinoma Neuroendocrine/anaplastic Molecular features?
63 Advanced Prostate Cancer To Personalize Therapy We Need Multiple therapy options Cognizance of disease heterogeneity Disease presentation and behavior Host and tumor response to treatment The ability to identify functionally distinct disease states that map to specific treatments A selection of active treatments Application of treatments not generally used in prostate cancer
64 Concluding Remarks With patient and tumor heterogeneity and 6 approved agents, there are opportunities to individual treatment selection and sequencing. There is not a single, correct sequence. Patient and tumor factors, prior treatment history, as well as patient and physician preferences drive treatment sequencing today.
65 Concluding Remarks (cont.) Biomarkers that robustly define resistance and response to therapy have the potential to improve on our current approach. Validation of emerging biomarkers would, for the first time, yield individualized, molecularly defined treatment sequences that might include: PARP inhibitors and/or platinum agents for DDR deficiency Checkpoint inhibitors in MMR deficiency Early chemotherapy in AR-V7 overexpressed disease Others
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationmcrpc in 2016 How to decide the optimal treatment? N. Mottet
mcrpc in 2016 How to decide the optimal treatment? N. Mottet Disclosures Conflict of interest Chairman EAU PCa guidelines..... Therefore I'm 100% biased Castrate-resistant prostate cancer (CRPC) Definition
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationConvegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena
Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationBoard Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending
Board Review 2017: Prostate Cancer Dana Rathkopf, MD Associate Attending www.mskcc.org The Paradox of Prostate Cancer High prevalence in the general population: over diagnosis of clinically insignificant
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationSEQUENCING IN METASTATIC PROSTATE CANCER TREATMENT
SEQUENCING IN METASTATIC PROSTATE CANCER TREATMENT Eleni Maragkouli, Medical Oncologist Oncology Department The University of Thessaly, Medical School University Hospital of Larissa, Greece Tumour volume
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationPatients Living Longer: The Promise of Newer Therapies
Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationMetastatic castrate-resistant prostate cancer: Toward a chronic disease
Metastatic castrate-resistant prostate cancer: Toward a chronic disease Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France General recommendations in CRPC Check serum Testosterone (should
More informationINTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER
INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER Daniel George, MD Professor of Medicine and Surgery Director of Genitourinary Oncology Program Duke Cancer Institute 1 Disclosures Consultant:
More informationUPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS
UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS Dr. Neal Shore, Carolina Urologic Research Centre, USA Assoc. Prof. Neeraj Agarwal, Huntsman Cancer Institute,
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationImmunotherapy and new agents in CRPC. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Immunotherapy and new agents in CRPC Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas, Astrazeneca, Bayer, Clovis,
More informationSUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments
SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More information- La Terapia Farmacologica -
XXV Congresso Nazionale AIRO Simposio AIRO-AIMN: Trattamento delle Metastasi Ossee nel Paziente con Tumore della Prostata "Ormonorefrattario": - La Terapia Farmacologica - Sergio Bracarda, Medical Oncology
More information*For reprints and all correspondence: Nobuaki Matsubara, Kashiwanoha, Kashiwa, Chiba , Japan.
Japanese Journal of Clinical Oncology, 2015, 45(8) 774 779 doi: 10.1093/jjco/hyv070 Advance Access Publication Date: 15 May 2015 Original Article Original Article A multicenter retrospective analysis of
More informationESMO SUMMIT AFRICA Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit
ESMO SUMMIT AFRICA 2018 Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche Merck Lilly 14 years of
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationHave we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer?
Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to
More informationManagement of castrate resistant disease; after first line hormone therapy fails
Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER. ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA
ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA MAY 2018 DISCLAIMER Please note: The views expressed within
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationRoberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
Il Trattamento della Malattia CRPC metastatica Terapie Radiometaboliche Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena AIOM: Gestione ottimale del Paziente con Carcinoma della
More informationProgress in Metastatic Prostate Cancer
Integrating Current & Novel Treatment Strategies for the Management of CRPC Charles J Ryan, MD Thomas Perkins Distinguished Professor of Medicine and Urology Helen Diller Family Comprehensive Cancer Center
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationFocus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi?
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano AGENDA Literature
More informationCirculating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego
National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationManagement of chronic pre-existing or treatment-emergent adverse events of the other systemic therapies. Michael J. Morris, MD
Management of chronic pre-existing or treatment-emergent adverse events of the other systemic therapies Michael J. Morris, MD www.mskcc.org Disclosures Research funding (institutional contracts): Sanofi
More informationEvolution or revolution in the treatment of prostate cancer
Evolution or revolution in the treatment of prostate cancer de Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Professor of Experimental Cancer Medicine Department of Medicine/ Drug Development Unit
More informationOptimizing Survival in Advanced Prostate Cancer. Welcome!
Optimizing Survival in Advanced Prostate Cancer Welcome! Optimizing Survival in Advanced Prostate Cancer Cora N. Sternberg Rome, Italy Programme Understanding the heterogeneity of prostate cancer Jack
More informationHave we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer?
Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationAdvancing Interdisciplinary Care in Prostate Cancer: Clinical Updates for Urology and Oncology Healthcare Professionals
Advancing Interdisciplinary Care in Prostate Cancer: Clinical Updates for Urology and Oncology Healthcare Professionals This transcript has been edited for style and clarity and includes all slides from
More informationProstate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy).
Thanks to: The Medical Educator Consortium Luis Raez, MD, Florida International University 15th ed. Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy). Mayer Fishman,
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationPresent and Future Perspectives in Treatment of mcrpc Patients
Present and Future Perspectives in Treatment of mcrpc Patients Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com Disclosures Astellas, Takeda, Janssen, Bouchara Recordati,
More informationSequencing treatment for metastatic prostate cancer
11 Sequencing treatment for metastatic prostate cancer SOPHIE MERRICK, STYLIANI GERMANOU, ROGER KIRBY AND SIMON CHOWDHURY In the past 10 years there have been significant advances in the understanding
More informationTreatment sequencing in metastatic castrate resistant prostate cancer
(2014) 16, 426 431 2014 AJA, SIMM & SJTU. All rights reserved 1008 682X www.asiaandro.com; www.ajandrology.com Prostate Cancer Open Access REVIEW Treatment sequencing in metastatic castrate resistant prostate
More informationMichiel H.F. Poorthuis*, Robin W.M. Vernooij*, R. Jeroen A. van Moorselaar and Theo M. de Reijke
First-line non-cytotoxic therapy in chemotherapynaive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials Michiel H.F. Poorthuis*, Robin
More informationThe Changing Landscape of Metastatic Prostate Cancer
The Changing Landscape of Metastatic Prostate Cancer Brian Lewis, MD, MPH, and Oliver Sartor, MD Abstract October 2014 marked the 10th anniversary of the publication of 2 seminal articles detailing the
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationOngoing trials that might change the standard of care in mcrpc
Ongoing trials that might change the standard of care in mcrpc Igor Tsaur University Medicine Mainz COI Off-label use of drugs, devices, or other agents: none Data from IRB-approved human research is presented:
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationReview of the Stampede Results. Charles Ryan MD University of California San Francisco
Review of the Stampede Results Charles Ryan MD University of California San Francisco Se#ng and hypothesis Se
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationPlease consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
More informationInitial hormone therapy (and more) for metastatic prostate cancer
Initial hormone therapy (and more) for metastatic prostate cancer Silke Gillessen, MD Medical Oncology Kantonsspital St.Gallen Switzerland silke.gillessen@kssg.ch Conflicts of interest Speakers Bureau
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Prostata: Oral Communications Emerging strategies and controversial topics in advanced prostate cancer Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationNavigating Prostate Cancer Therapy. Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA
Navigating Prostate Cancer Therapy Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA Disclosures In compliance with accreditation, we require the following disclosures to the
More information